ArticlePloS one2018
Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- CD56 negativity is associated with worse survival outcomes in patients with multiple myeloma: a meta-analysis.World journal of surgical oncology · 2026Pooled it
- The Role of CD56 as an Immunophenotypic Marker in the Clinical Course of Multiple Myeloma.Journal of clinical medicine · 2026Article
- Evaluation of CD56 and CD117 Double-Positivity as a Predictor of Poor Prognosis in Multiple Myeloma Patients: A Retrospective AnalysisTurkish journal of haematology : official journal of Turkish Society of Haematology · 2024Article
- Activating transcription factor 4 regulates hypoxia inducible factor 1α in chronic hypoxia in pancreatic cancer cells.Oncology reports · 2023Article
- Immunophenotypic expression profile of multiple myeloma cases at a tertiary hospital in Nairobi Kenya.Frontiers in medicine · 2023Article
- Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation.BMC cancer · 2022Article
- Dual Negativity of CD56 and CD117 Links to Unfavorable Cytogenetic Abnormalities and Predicts Poor Prognosis in Multiple Myeloma.Journal of clinical medicine · 2022Article
- Multiple Myeloma Immunophenotype Related to Chromosomal Abnormalities Used in Risk Assessment.Diagnostics (Basel, Switzerland) · 2022Article
- CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival.Journal of clinical medicine · 2022Article
- The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era.Medical oncology (Northwood, London, England) · 2020Article
- A putative competing endogenous RNA network in cisplatin-resistant lung adenocarcinoma cells identifying potentially rewarding research targets.Oncology letters · 2020Article
- Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.Cancer science · 2020Article
- Uncovering Prognosis-Related Genes and Pathways by Multi-Omics Analysis in Lung Cancer.Biomolecules · 2020Article
- [Prognostic significance of CD56 and CD117 expression in patients with newly diagnosed multiple myeloma treated with bortezomib-based first-line therapy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019Article
- High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment.Journal of clinical medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bortezomib (Btz) is an active agent used to treat multiple myeloma (MM). Not all patients who receive Btz-containing therapy show a favorable response. Interaction of cellular adhesion molecules with MM and bone marrow stromal cells is crucial for the survival of MM cells. However, little is known about the role of these molecules in the sensitivity of MM to Btz-containing therapy. Thus, we evaluated the correlation between the level of cellular adhesion molecules in MM cells and the efficacy of Btz plus dexamethasone (Bd) therapy. The expression of the neural cell adhesion molecule gene (NCAM, also known as CD56), ITGA4, CXCR4, and other genes were analyzed in 74 samples of primary MM cells collected from patients before they received Bd therapy. Of the eight genes tested, expression of NCAM was lower among patients who responded poorly to Bd therapy. In vitro expression of NCAM induced by transfection of MM cells enhanced their sensitivity to Btz treatment by causing accumulation of polyubiquitinated proteins. Our results indicate that expression of NCAM is associated with better response to Btz treatment and is a promising candidate biomarker for predicting response to therapies involving Btz.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.